These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32218998)

  • 1. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization.
    Konopka-Anstadt JL; Campagnoli R; Vincent A; Shaw J; Wei L; Wynn NT; Smithee SE; Bujaki E; Te Yeh M; Laassri M; Zagorodnyaya T; Weiner AJ; Chumakov K; Andino R; Macadam A; Kew O; Burns CC
    NPJ Vaccines; 2020; 5(1):26. PubMed ID: 32218998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation.
    Thompson KM; Kalkowska DA; Badizadegan K
    Front Public Health; 2023; 11():1098419. PubMed ID: 37033033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.
    Kalkowska DA; Pallansch MA; Wilkinson A; Bandyopadhyay AS; Konopka-Anstadt JL; Burns CC; Oberste MS; Wassilak SGF; Badizadegan K; Thompson KM
    Risk Anal; 2021 Feb; 41(2):329-348. PubMed ID: 33174263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.
    Van Damme P; De Coster I; Bandyopadhyay AS; Revets H; Withanage K; De Smedt P; Suykens L; Oberste MS; Weldon WC; Costa-Clemens SA; Clemens R; Modlin J; Weiner AJ; Macadam AJ; Andino R; Kew OM; Konopka-Anstadt JL; Burns CC; Konz J; Wahid R; Gast C
    Lancet; 2019 Jul; 394(10193):148-158. PubMed ID: 31174831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine.
    Blake IM; Pons-Salort M; Molodecky NA; Diop OM; Chenoweth P; Bandyopadhyay AS; Zaffran M; Sutter RW; Grassly NC
    N Engl J Med; 2018 Aug; 379(9):834-845. PubMed ID: 30157398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, July 2019-February 2020.
    Alleman MM; Jorba J; Greene SA; Diop OM; Iber J; Tallis G; Goel A; Wiesen E; Wassilak SGF; Burns CC
    MMWR Morb Mortal Wkly Rep; 2020 Apr; 69(16):489-495. PubMed ID: 32324719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation.
    Kalkowska DA; Wassilak SG; Wiesen E; F Estivariz C; Burns CC; Badizadegan K; Thompson KM
    Gates Open Res; 2023; 7():55. PubMed ID: 37547300
    [No Abstract]   [Full Text] [Related]  

  • 8. Modeling the spread of circulating vaccine-derived poliovirus type 2 outbreaks and interventions: A case study of Nigeria.
    Sun Y; Keskinocak P; Steimle LN; Kovacs SD; Wassilak SG
    Vaccine X; 2024 Jun; 18():100476. PubMed ID: 38617838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
    Kalkowska DA; Pallansch MA; Wassilak SGF; Cochi SL; Thompson KM
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A136-A141. PubMed ID: 33994237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.
    Kalkowska DA; Wassilak SGF; Wiesen E; Burns CC; Pallansch MA; Badizadegan K; Thompson KM
    Risk Anal; 2024 Feb; 44(2):366-378. PubMed ID: 37344934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2021-December 2022.
    Bigouette JP; Henderson E; Traoré MA; Wassilak SGF; Jorba J; Mahoney F; Bolu O; Diop OM; Burns CC
    MMWR Morb Mortal Wkly Rep; 2023 Apr; 72(14):366-371. PubMed ID: 37022974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk of type 2 oral polio vaccine use in post-cessation outbreak response.
    McCarthy KA; Chabot-Couture G; Famulare M; Lyons HM; Mercer LD
    BMC Med; 2017 Oct; 15(1):175. PubMed ID: 28974220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials.
    Wahid R; Mercer LD; De Leon T; DeAntonio R; Sáez-Llorens X; Macadam A; Chumakov K; Strating J; Koel B; Konopka-Anstadt JL; Oberste MS; Burns CC; Andino R; Tritama E; Bandyopadhyay AS; Aguirre G; Rüttimann R; Gast C; Konz JO
    Lancet Microbe; 2022 Dec; 3(12):e912-e921. PubMed ID: 36332645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence.
    Yeh MT; Bujaki E; Dolan PT; Smith M; Wahid R; Konz J; Weiner AJ; Bandyopadhyay AS; Van Damme P; De Coster I; Revets H; Macadam A; Andino R
    Cell Host Microbe; 2020 May; 27(5):736-751.e8. PubMed ID: 32330425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.
    De Coster I; Leroux-Roels I; Bandyopadhyay AS; Gast C; Withanage K; Steenackers K; De Smedt P; Aerssens A; Leroux-Roels G; Oberste MS; Konopka-Anstadt JL; Weldon WC; Fix A; Konz J; Wahid R; Modlin J; Clemens R; Costa Clemens SA; Bachtiar NS; Van Damme P
    Lancet; 2021 Jan; 397(10268):39-50. PubMed ID: 33308429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outbreak response strategies with type 2-containing oral poliovirus vaccines.
    Kalkowska DA; Wassilak SGF; Pallansch MA; Burns CC; Wiesen E; Durry E; Badizadegan K; Thompson KM
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A142-A152. PubMed ID: 36402659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2016 May; 16():231. PubMed ID: 27230071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Quantitative One-Step RT-PCR Method for the Detection of Sabin 2 Virus Contamination in a Novel Oral Poliovirus Vaccine Type 2.
    Manukyan H; Tritama E; Wahid R; Ansari A; Konz J; Chumakov K; Laassri M
    Vaccines (Basel); 2021 Jun; 9(7):. PubMed ID: 34201447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.
    Sáez-Llorens X; Bandyopadhyay AS; Gast C; Leon T; DeAntonio R; Jimeno J; Caballero MI; Aguirre G; Oberste MS; Weldon WC; Konopka-Anstadt JL; Modlin J; Bachtiar NS; Fix A; Konz J; Clemens R; Costa Clemens SA; Rüttimann R
    Lancet; 2021 Jan; 397(10268):27-38. PubMed ID: 33308427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3.
    Yeh MT; Smith M; Carlyle S; Konopka-Anstadt JL; Burns CC; Konz J; Andino R; Macadam A
    Nature; 2023 Jul; 619(7968):135-142. PubMed ID: 37316671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.